PL001 / Pell Bio-Med Techno - LARVOL DELTA

Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma (clinicaltrials.gov) - P1/2 | N=49 | Recruiting | Sponsor: Pell Bio-Med Technology Co., Ltd. | Trial completion date: Mar 2026 ➔ Mar 2027 | Trial primary completion date: Dec 2025 ➔ Dec 2026

Trial completion date • Trial primary completion date • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Mediastinal Large B-Cell Lymphoma

Pell Biomedical was listed on the Innovation Board, with an underwriting price of 98 yuan, and the second phase clinical trial of lymphoma is completed by the end of the year. [Google translation] (stock.yahoo) - "Pell Biomedical...will be listed on the Innovation Board of the Taiwan Stock Exchange as 'Pell Biotech-Chuang'...tomorrow (8th), becoming the first company on the Innovation Board Cell gene therapy new drug research and development company. Pell's product with the fastest development progress is PL001, a CD19 CAR-T targeting the B cell surface antigen CD19 to treat B cell lymphoma. It is currently in the second phase of clinical trials and is expected to be completed by the end of this year."

Trial completion date • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma (clinicaltrials.gov) - P1/2 | N=49 | Recruiting | Sponsor: Pell Bio-Med Technology Co., Ltd. | Trial completion date: Sep 2024 ➔ Mar 2026 | Trial primary completion date: Aug 2024 ➔ Dec 2025

CAR T-Cell Therapy • IO biomarker • Trial completion date • Trial primary completion date • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T) for Relapsed or Refractory B-cell Lymphoma (clinicaltrials.gov) - P1/2 | N=49 | Recruiting | Sponsor: Pell Bio-Med Technology Co., Ltd. | Not yet recruiting ➔ Recruiting

CAR T-Cell Therapy • Enrollment open • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD19